Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Growth Factors ; 32(3-4): 123-9, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25060036

RESUMO

BACKGROUND: Ataxia telangiectasia (A-T) is a devastating human recessive disorder characterised by progressive cerebellar ataxia, immunodeficiency, genetic instability, and cancer susceptibility. In addition, many patients suffer from growth failure. METHODS: We analyzed growth and IGF-1/BP3 levels of 24 A-T-patients compared with an age-matched group of healthy controls (n = 36). RESULTS: Ten (41.7%) A-T patients and none of healthy controls had an IGF-1 level below the 3rd percentile for age. The growth hormone (GH) stimulation tests revealed a severe GH deficiency with no increase of >5 ng/ml in six of the ten A-T patients. The IGF-1 generation tests revealed normal increases in IGF-1 values in all patients. CONCLUSION: Our results show that a disturbance in the GH/IGF-1 axis was present in 58.3% of A-T patients. Low levels of GH were the result of reduced central GH secretion. GH treatment may be a therapeutic option for A-T patients with severe growth failure.


Assuntos
Ataxia Telangiectasia/sangue , Estatura , Hormônio do Crescimento Humano/deficiência , Adolescente , Ataxia Telangiectasia/diagnóstico , Ataxia Telangiectasia/patologia , Criança , Pré-Escolar , Feminino , Hormônio do Crescimento Humano/sangue , Humanos , Proteína 3 de Ligação a Fator de Crescimento Semelhante à Insulina/sangue , Fator de Crescimento Insulin-Like I/metabolismo , Masculino
2.
BMC Pulm Med ; 14: 93, 2014 May 29.
Artigo em Inglês | MEDLINE | ID: mdl-24884546

RESUMO

BACKGROUND: Ataxia telangiectasia (A-T) is a rare but devastating and progressive disorder characterized by cerebellar dysfunction, lymphoreticular malignancies and recurrent sinopulmonary infections. In A-T, disease of the respiratory system causes significant morbidity and is a frequent cause of death. METHODS: We used a self-limited murine model of hydrochloric acid-induced acute lung injury (ALI) to determine the inflammatory answer due to mucosal injury in Atm (A-T mutated)- deficient mice (Atm(-/-)). RESULTS: ATM deficiency increased peak lung inflammation as demonstrated by bronchoalveolar lavage fluid (BALF) neutrophils and lymphocytes and increased levels of BALF pro-inflammatory cytokines (e.g. IL-6, TNF). Furthermore, bronchial epithelial damage after ALI was increased in Atm(-/-) mice. ATM deficiency increased airway resistance and tissue compliance before ALI was performed. CONCLUSIONS: Together, these findings indicate that ATM plays a key role in inflammatory response after airway mucosal injury.


Assuntos
Lesão Pulmonar Aguda/imunologia , Lesão Pulmonar Aguda/patologia , Ataxia Telangiectasia/imunologia , Imunidade nas Mucosas/fisiologia , Animais , Ataxia Telangiectasia/patologia , Proteínas Mutadas de Ataxia Telangiectasia/deficiência , Biópsia por Agulha , Citocinas/imunologia , Modelos Animais de Doenças , Imuno-Histoquímica , Masculino , Camundongos , Camundongos Endogâmicos , Neutrófilos/imunologia , Distribuição Aleatória , Valores de Referência , Fator de Necrose Tumoral alfa/imunologia
3.
Growth Factors ; 27(5): 265-73, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19626507

RESUMO

Growth hormone (GH) is important for cell growth and differentiation, has multiple effects on lymphoid tissue and may promote blast cell proliferation and cancer development. We studied the effect of GH on longevity and tumour formation in Atm-deficient mice, an established model of the human cancer prone syndrome ataxia telangiectasia (AT). AT is a devastating recessive disorder that is characterized by progressive cerebellar ataxia, immunodeficiency, chromosomal instability and cancer susceptibility. Since AT patients also show endocrinological abnormalities the question has been raised as to whether GH therapy could be beneficial and/or increase the cancer risk in AT. We found that treatment with GH significantly increased longevity of Atm-deficient mice. In addition, GH ameliorated locomotoric behaviour and improved T-cell immunity. Thus, our data demonstrated that GH treatment is not necessarily accompanied by increased cancer development in diseases with chromosomal instability and cancer susceptibility and might be beneficial for AT patients.


Assuntos
Ataxia Telangiectasia/tratamento farmacológico , Proteínas de Ciclo Celular , Proteínas de Ligação a DNA , Hormônio do Crescimento/uso terapêutico , Proteínas Serina-Treonina Quinases , Proteínas Recombinantes/uso terapêutico , Neoplasias do Timo , Proteínas Supressoras de Tumor , Animais , Ataxia Telangiectasia/complicações , Proteínas Mutadas de Ataxia Telangiectasia , Proteínas de Ciclo Celular/genética , Proteínas de Ligação a DNA/deficiência , Proteínas de Ligação a DNA/genética , Modelos Animais de Doenças , Feminino , Hormônio do Crescimento/administração & dosagem , Hormônio do Crescimento/genética , Humanos , Linfoma/etiologia , Linfoma/genética , Linfoma/fisiopatologia , Linfoma/prevenção & controle , Masculino , Camundongos , Proteínas Serina-Treonina Quinases/deficiência , Proteínas Serina-Treonina Quinases/genética , Ratos , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/genética , Linfócitos T/imunologia , Neoplasias do Timo/etiologia , Neoplasias do Timo/genética , Neoplasias do Timo/fisiopatologia , Neoplasias do Timo/prevenção & controle , Resultado do Tratamento , Proteínas Supressoras de Tumor/deficiência , Proteínas Supressoras de Tumor/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA